Table 3 Demographic data
Data | N (%) | Median (IQR) | Mean ± SD | P-value | |
|---|---|---|---|
UNMISS + RT (N = 14) | RT Alone (N = 9) | ||
Age (years) | 53.5 (50.5–60.75) | 66 (49–71) | 0.361 |
Female | 11 (78.5) | 7 (77.78) | 0.639 |
Primary tumor | 0.326 | ||
Breast cancer | 8 (57.14) | 4 (44.44) | |
Lung cancer | 5 (35.71) | 2 (22.22) | |
Renal cell carcinoma | 1 (7.15) | - | |
Thyroid | - | 1 (11.11) | |
Prostate | - | 1 (11.11) | |
Nasopharynx | - | 1 (11.11) | |
NESMS | 0.198 | ||
(1 yr postop survival rate) | |||
0 (18.5%) | 2 (14.30) | - | |
1 (34.9%) | 5 (35.71) | 7 (77.78) | |
2 (46.2%) | 5 (35.71) | 2 (22.22) | |
3 (68.3%) | 2 (14.30) | - | |
Tomita | 0.205 | ||
(Avg survival, months) | |||
2–4 (19 months) | 4 (28.58) | - | |
5–7 (16 months) | 5 (35.71) | 5 (55.56) | |
8–10 (3 months) | 5 (35.71) | 4 (44.44) | |
Pre-treatment VAS | 6.71 ± 2.20 | 7.66 ± 3.01 | 0.439 |